. Author manuscript; available in PMC: 2011 Mar 15.

Published in final edited form as: Adolesc Med State Art Rev. 2010 Aug;21(2):347–xi.

Table 2.

Vaccine efficacy of cervarix against HPV 16/18-associated high-grade cervical disease

	Vaccine		Placebo		Observed Efficacy, % (96.1% CI)
	n	Cases	n	Cases	Observed Efficacy, % (96.1% CI)
Per Protocol^a
CIN 2 or worse	7344	4	7312	56	92.9 (79.9–98.3)
CIN 2 or worse, corrected for lesion HPV type^b	7344	1	7312	53	98.1 (88.4–100.0)
Intention to treat^c
CIN 2 or worse	8667	82	8682	174	52.8 (37.–64.7)

Per protocol must have met all inclusion criteria naïve to HPV vaccine types completed 3 doses and started counting case day after third vaccination.

HPV 16/18 in lesion and in preceding sample if multiple types found in lesion.

Referred to as total vaccinated cohort.³⁰ Included women who were given at least one does, case counting occurred day after first vaccination and included women regardless of serostatus or DNA status at visit 0.